A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. 2006

Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
Department of Environmental Health, Boston University School of Public Health, Boston, MA 02118, USA.

The aryl hydrocarbon receptor (AhR) is an evolutionarily conserved transcription factor bound and activated by ubiquitous environmental pollutants. Historically, the AhR has been studied for its transcriptional regulation of genes encoding cytochrome P450 enzymes, which metabolize many of these chemicals into mutagenic and toxic intermediates. However, recent studies demonstrate that the AhR plays an important role in the biology of several cell types in the absence of environmental chemicals. Here, this paradigm shift is discussed in the context of a putative role for the AhR in mammary gland tumorigenesis. Data demonstrating high levels of constitutively active AhR in mammary tumors are summarized. Particular focus is placed on the likelihood that the AhR contributes to ongoing mammary tumor cell growth and on the possibility that the AhR inhibits apoptosis while promoting transition to an invasive, metastatic phenotype. A working model is proposed that may help explain the sometimes contradictory outcomes observed after AhR manipulation and that serves as a blueprint for the design of therapeutics which target the AhR in breast cancer. The theme that malignant cells reveal the functions for which the AhR has been evolutionarily conserved is presented throughout this discussion.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015674 Mammary Neoplasms, Animal Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL). Animal Mammary Carcinoma,Mammary Carcinoma, Animal,Mammary Neoplasms,Neoplasms, Mammary,Animal Mammary Carcinomas,Animal Mammary Neoplasm,Animal Mammary Neoplasms,Carcinoma, Animal Mammary,Carcinomas, Animal Mammary,Mammary Carcinomas, Animal,Mammary Neoplasm,Mammary Neoplasm, Animal,Neoplasm, Animal Mammary,Neoplasm, Mammary,Neoplasms, Animal Mammary
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D018336 Receptors, Aryl Hydrocarbon Cytoplasmic proteins that bind certain aryl hydrocarbons, translocate to the nucleus, and activate transcription of particular DNA segments. AH receptors are identified by their high-affinity binding to several carcinogenic or teratogenic environmental chemicals including polycyclic aromatic hydrocarbons found in cigarette smoke and smog, heterocyclic amines found in cooked foods, and halogenated hydrocarbons including dioxins and polychlorinated biphenyls. No endogenous ligand has been identified, but an unknown natural messenger with a role in cell differentiation and development is suspected. AH Receptors,Aryl Hydrocarbon Receptors,Dioxin Receptors,Receptors, AH,Receptors, Dioxin,TCDD Receptors,AH Receptor,Aryl Hydrocarbon Receptor,Dioxin Receptor,Polyaromatic Hydrocarbon Receptor,Polyaromatic Hydrocarbon Receptors,Receptors, 2,3,7,8-Tetrachlorodibenzo-p-dioxin,Receptors, Polyaromatic Hydrocarbon,Receptors, TCDD,TCDD Receptor,Receptor, AH,Receptor, Aryl Hydrocarbon,Receptor, Dioxin,Receptor, Polyaromatic Hydrocarbon,Receptor, TCDD

Related Publications

Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
November 1976, Cancer research,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
May 2016, Environmental health perspectives,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
August 1994, Trends in endocrinology and metabolism: TEM,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
December 2005, Journal of cellular biochemistry,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
September 1993, Molecular pharmacology,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
August 2016, Molecular cancer research : MCR,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
April 1977, Chemico-biological interactions,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
January 2004, Advances in cancer research,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
April 2018, Journal of proteome research,
Jennifer J Schlezinger, and Donghui Liu, and Marganit Farago, and David C Seldin, and Karine Belguise, and Gail E Sonenshein, and David H Sherr
August 2017, Hormones & cancer,
Copied contents to your clipboard!